Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/3/2009

significant problem with recurrence in CDI patients, Optimer believes that the medical community is placing greater emphasis on global cure, defined as a cure without a recurrence. The global cure rate of fidaxomicin versus vancomycin was 77.7% versus 67.1% (p=0.006) in Optimer's North American Phase 3 trial.
  • Optimer expects to complete enrollment of the second Phase 3 trial of fidaxomicin in 2009, and anticipates reporting top-line data in the first quarter of 2010. The Company continues to engage in partnering discussions regarding fidaxomicin to maximize its value.
  • Optimer recently entered into a number of transactions involving OBI, the Company's Taiwan subsidiary, to provide OBI with funding for the development of two of Optimer's early-stage, non-core programs, OPT-88 and OPT-822/821, and to allow Optimer to focus on its late-stage anti-infective programs, fidaxomicin and Pruvel. Pursuant to these transactions, Optimer assigned to OBI certain patent rights, information and know-how related to OPT-88, a preclinical product candidate for the treatment of osteoarthritis, and OPT-822/821, a carbohydrate-based cancer immunotherapy product candidate. Optimer is eligible to receive up to $10 million in milestone payments and single-digit royalties on net sales for any product developed and commercialized under the programs. To provide capital for OBI's development of OPT-88 and OPT-822/821, Optimer and a group of new investors purchased approximately $3.7 million and $2.5 million, respectively, in new OBI common shares. Also in connection with the transactions, Optimer sold forty percent of its pre-transaction OBI common shares to the new investors for proceeds of $2.1 million. Optimer maintains a sixty percent ownership interest in OBI following the completion of these transactions.
  • Recent Corporate Highlights

    • Three fidaxomicin-related abstracts from Optimer's North American Phase 3 study in patients w
      '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
    2. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
    3. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
    4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
    5. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
    6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
    7. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
    8. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
    9. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
    10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
    11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
    (Date:12/19/2014)... Mass. , Dec. 19, 2014 Decision ... market will grow at a 12 percent compound annual ... result of the aging population and the increasing adoption ... Latin America will also spur demand for ... of dental implant and periodontal treatments. Other ...
    (Date:12/19/2014)... 18, 2014 Today, TiFiber, ... pilot production facility and future company headquarters in ... innovative new materials that safely and effectively control ... because of its historic, strong support for manufacturing, ... attract leading edge, technology-based companies such as TiFiber. ...
    (Date:12/19/2014)... MA (PRWEB) December 18, 2014 Reports ... in the United States suffer from one or more ... asthma, or cancer. Medication can address some of these ... daily activities that many sufferers face. While implanted nerve ... and stimulate the whole nerve, which can induce side ...
    Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2
    ... could improve the life of the lithium batteries ... players, and mobile phones. Research to be published ... Nanomanufacturing - demonstrates that carbon nanotubes can prevent ... time. , Researchers at the Shenyang National Laboratory ...
    ... 10 Hologic, Inc.,(Nasdaq: HOLX ) today ... presenting at the Sun Trust Robinson Humphrey,s 37th ... Ritz-Carlton Hotel in,Buckhead, GA., Interested parties are ... of,Hologic,s investor presentation on Wednesday, April 16, 2008, ...
    ... are 14 prescription drugs that,exceeded $20 billion in sales in ... in four years. Prescription to OTC switches,were frequent in 2006 ... of the Rx to OTC Switch: Market Analysis and Product ... Rx to OTC are forecast to reach $5 billion in ...
    Cached Biology Technology:Sweet nanotech batteries 2Hologic to Present at the Sun Trust Robinson Humphrey's 37th Annual Institutional Conference 2Use of Rx to OTC Switch as Product Management Tactic Enjoys Comeback 2
    (Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
    (Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
    (Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
    Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
    ... ahead of a deadly disease that has wiped out more ... continue to discover new frog species in Panama: Pristimantis ... adnus from Darien Province near the Colombian border. , ... world. Then they identified the cause: a fungal disease called ...
    ... Irvine scientists have created an eight-layer, early-stage retina from ... to be made from stem cells. It also ... retinas to treat eye disorders such as retinitis pigmentosa ... a complex structure consisting of many cell types," said ...
    ... Medicine have identified in mice a previously unknown protective ... clots and other blockages from the brain. The findings ... age-related cognitive decline, Alzheimer,s disease and recovery from stroke. ... May 27 issue of Nature by Jaime ...
    Cached Biology News:2 new frog species discovered in Panama's fungal war zone 2UCI researchers create retina from human embryonic stem cells 2Researchers discover new mechanism for clearing blockages from smallest blood vessels 2
    ... and ES1301 mutS are mismatch repair minus ... strains prevents repair of the newly synthesized ... efficiencies and making them helpful in such ... II Mutagenesis Systems. Both ES1301 and BMH ...
    Request Info...
    ... ExcelGel DNA Analysis Kit, 1. ... polymorphisms and high resolution DNA typing. ... set-up and clean-up. *Precast, plastic-backed gels ... handling convenience and detection sensitivity. ...
    For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
    Biology Products: